NasdaqGS:TYRABiotechs
Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook
Boone Capital Management has disclosed a significant new position in Tyra Biosciences.
The investment comes as Tyra Biosciences advances multiple clinical trials centered on FGFR3 biology.
The move highlights fresh institutional interest in NasdaqGS:TYRA at a current share price of $37.15.
For readers tracking Tyra Biosciences, the company now sits at a share price of $37.15 with substantial recent share price momentum, including a 26.4% return over the past 30 days and 38.7% year to date...